Brief: PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial
09/06/2025 13:03
June 9 (Reuters) - PolyPid Ltd PYPD.O: POLYPID ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SHIELD II TRIAL: D-PLEX₁₀₀ DEMONSTRATED SIGNIFICANT REDUCTION IN SURGICAL SITE INFECTIONS AND SUCCESSFULLY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS POLYPID LTD - D-PLEX(100) MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIAL POLYPID LTD - TO SUBMIT NDA TO FDA IN EARLY 2026 POLYPID LTD - TRIAL SHOWS 58% REDUCTION IN SURGICAL SITE INFECTIONS WITH D-PLEX(100) POLYPID LTD - STUDY SHOWS 38% REDUCTION IN PRIMARY ENDPOINT EVENTS WITH D-PLEX(100) POLYPID LTD - NO SAFETY CONCERNS RAISED BY INDEPENDENT DATA SAFETY MONITORING BOARD IN SHIELD II Source text: ID:nGNX8tbD4K Further company coverage: PYPD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA